Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Josep M Llovet^{1

2

3}, Augusto Villanueva¹, Jorge A Marrero⁴, Myron Schwartz¹, Tim Meyer⁵, Peter R Galle⁶, Riccardo Lencioni^{7

8}, Tim F Greten⁹, Masatoshi Kudo¹⁰, Sumithra J Mandrekar¹¹, Andrew X Zhu^{12

13}, Richard S Finn¹⁴, Lewis R Roberts¹⁵; AASLD Panel of Experts on Trial Design in HCC

Affiliations

¹ Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
² Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
³ Institució Catalana d'Estudis Avançats (ICREA), Barcelona, Spain.
⁴ UT Southwestern Medical Center, Dallas, TX.
⁵ Department Oncology, University College London Cancer Institute, London, UK.
⁶ Department of Internal Medicine, Mainz University Medical Center, Mainz, Germany.
⁷ Department of Radiology, University of Pisa School of Medicine, Pisa, Italy.
⁸ Miami Cancer Institute, Miami, FL.
⁹ Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
¹⁰ Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
¹¹ Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
¹² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
¹³ Jiahui International Cancer Center, Shanghai, China.
¹⁴ Geffen School of Medicine at UCLA, Los Angeles, CA.
¹⁵ Gastroenterology & Hepatology Department, Mayo Clinic, Rochester, MN.

Review

Josep M Llovet et al. Hepatology. 2021 Jan.

. 2021 Jan:73 Suppl 1:158-191.

doi: 10.1002/hep.31327. Epub 2020 Sep 9.

¹ Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
² Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
³ Institució Catalana d'Estudis Avançats (ICREA), Barcelona, Spain.
⁴ UT Southwestern Medical Center, Dallas, TX.
⁵ Department Oncology, University College London Cancer Institute, London, UK.
⁶ Department of Internal Medicine, Mainz University Medical Center, Mainz, Germany.
⁷ Department of Radiology, University of Pisa School of Medicine, Pisa, Italy.
⁸ Miami Cancer Institute, Miami, FL.
⁹ Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
¹⁰ Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
¹¹ Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
¹² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
¹³ Jiahui International Cancer Center, Shanghai, China.
¹⁴ Geffen School of Medicine at UCLA, Los Angeles, CA.
¹⁵ Gastroenterology & Hepatology Department, Mayo Clinic, Rochester, MN.

No abstract available

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
1. Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450-1462.
1. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;56:908-943.
1. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-750.
1. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.